Physician profile
Arturo Prada
NPI 1427030147
$4,922.66
in general payments reported to CMS, 2019-2025
35 companies · $470 in 2025
The $470 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $940 · 2020: $515 · 2021: $606 · 2022: $665 · 2023: $752 · 2024: $975 · 2025: $470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,196.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,196.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $616.49 | 2019-2025 | Farxiga, Airsupra |
| Amgen INC. | $562.28 | 2019-2025 | Tavneos, Prolia, Evenity |
| Bayer Healthcare Pharmaceuticals INC. | $410.71 | 2021-2025 | |
| Otsuka America Pharmaceutical, INC. | $368.42 | 2019-2025 | Jynarque |
| Merck Sharp & Dohme LLC | $355.31 | 2019-2024 | Verquvo |
| Lilly USA, LLC | $265.13 | 2020-2025 | Mounjaro, Trulicity, Jardiance |
| Amarin Pharma, INC. | $201.59 | 2019-2022 | |
| Travere Therapeutics, INC. | $179.01 | 2023-2025 | |
| Prodigy Surgical Distribution, INC. | $166.12 | 2024 | |
| Glaxosmithkline, LLC. | $162.07 | 2020-2025 | Trelegy Ellipta, Arexvy |
| Vifor Pharma, INC. | $142.17 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $139.53 | 2019-2020 | |
| Mallinckrodt Hospital Products INC. | $112.89 | 2021-2022 | |
| Sanofi-Aventis U.S. LLC | $110.04 | 2019 | |
| Fresenius USA Marketing, INC. | $93.60 | 2019-2024 | Velphoro |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $93.04 | 2024-2025 | Wegovy |
| Exact Sciences Corporation | $92.90 | 2023-2025 | Cologuard Collection Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $89.66 | 2024-2025 | Jardiance |
| Abbvie INC. | $87.34 | 2023-2024 | |
| Horizon Therapeutics Plc | $87.08 | 2020-2023 | |
| Ardelyx, INC. | $77.10 | 2024-2025 | Ibsrela |
| Calliditas Therapeutics US INC. | $66.69 | 2023-2024 | Tarpeyo |
| Aurinia Pharma U.S., INC. | $56.50 | 2021-2022 | |
| Abbott Laboratories | $55.76 | 2022-2023 | Freestyle Libre 3 |
| Daiichi Sankyo INC. | $52.21 | 2021-2024 | Injectafer |
| Novartis Pharmaceuticals Corporation | $48.05 | 2021-2025 | |
| Pfizer INC. | $43.76 | 2019-2022 | |
| Apellis Pharmaceuticals, INC. | $34.69 | 2025 | Empaveli |
| E.R. Squibb & Sons, L.L.C. | $27.83 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $22.15 | 2019 | |
| Esperion Therapeutics, INC. | $21.20 | 2021 | |
| Nxstage Medical, INC. | $20.91 | 2023 | Nxstage System One, Liberty Select Cycler |
| Eusa Pharma (US) LLC | $20.79 | 2022 | |
| Recordati_rare_diseases_inc. | $20.79 | 2022 | |
| Allergan, INC. | $18.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arturo Prada listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.